SWM
BLPH

SeaCrest Wealth Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

SeaCrest Wealth Management’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-200
Closed -$2K – 2286
2018
Q4 		$2K Hold
200
– – ﹤0.01% 1955
2018
Q3 		$3K Buy
+200
New +$4.75K ﹤0.01% 2024

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SeaCrest Wealth Management's BLPH Position: Q1 2019 in Review

SeaCrest Wealth Management sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q1 2019, closing a stake of 200 shares — an estimated $2K sold.

SeaCrest Wealth Management first reported a position in BLPH in Q3 2018 and held it in 2 quarters. The position peaked at $3K in Q3 2018. 26 funds tracked by Wall St. Rank hold BLPH as of Q1 2019.

  • SeaCrest Wealth Management reported no remaining Bellerophon Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • SeaCrest Wealth Management sold 200 Bellerophon Therapeutics, Inc. shares in Q1 2019, an estimated $2K.
  • SeaCrest Wealth Management first reported a position in Bellerophon Therapeutics, Inc. in Q3 2018 and held it in 2 quarters.
  • SeaCrest Wealth Management's Bellerophon Therapeutics, Inc. position peaked at $3K in Q3 2018.
  • 26 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q1 2019.

Based on SeaCrest Wealth Management's 13F filing for Q1 2019, filed 10 May 2019.